MAIA Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
MAIA Biotechnology, Inc. (MAIA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 400.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-10
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 400.00K shares.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 200.93K shares, a 10.46% decline year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 300.94K shares.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 910.87K shares, a 0.77% increase from fiscal 2024.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 903.92K shares, a 124.99% increase from fiscal 2023.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 401.75K shares, a 2278.93% increase from fiscal 2022.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 16.89K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 400.00K shares 10-Q · filed 2026-08-10 | 600.93K shares derived: sum of 3 quarters · filed 2026-08-10 | 901.87K shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 400.00K shares 10-Q · filed 2026-05-11 | 600.93K shares derived: sum of 2 quarters · filed 2026-05-11 | 901.87K shares derived: sum of 3 quarters · filed 2026-05-11 | 1.31M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 200.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 501.87K shares derived: sum of 2 quarters · filed 2026-03-23 | 910.87K shares derived: sum of 3 quarters · filed 2026-03-23 | 910.87K shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 300.94K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 709.94K shares derived: sum of 2 quarters · filed 2025-11-07 | 709.94K shares 10-Q · filed 2025-11-07 | 934.34K shares derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | 409.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 409.00K shares 10-Q · filed 2025-08-11 | 633.39K shares derived: sum of 3 quarters · filed 2025-08-11 | 633.39K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-09 | 224.39K shares derived: sum of 2 quarters · filed 2025-05-09 | 224.39K shares derived: sum of 3 quarters · filed 2025-05-09 | 230.29K shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 224.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | 224.39K shares derived: sum of 2 quarters · filed 2025-03-21 | 230.29K shares derived: sum of 3 quarters · filed 2025-03-21 | 903.92K shares 10-K · filed 2025-03-21 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 5.90K shares derived: sum of 2 quarters · filed 2024-11-12 | 679.53K shares 10-Q · filed 2024-11-12 | 998.26K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 5.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 679.53K shares 10-Q · filed 2024-08-09 | 998.26K shares derived: sum of 3 quarters · filed 2024-08-09 | 1.04M shares derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | 673.63K shares 10-Q · filed 2024-05-14 | 992.36K shares derived: sum of 2 quarters · filed 2024-05-14 | 1.03M shares derived: sum of 3 quarters · filed 2024-05-14 | |
| 2023-12-31 | 318.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 355.94K shares derived: sum of 2 quarters · filed 2024-03-21 | 401.75K shares 10-K · filed 2024-03-21 | |
| 2023-09-30 | 37.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 83.02K shares 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | 45.81K shares 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-24 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-24 | 16.89K shares 10-K · filed 2023-03-24 | |
| 2022-09-30 | 0.00 shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-02-06 | 16.89K shares 10-Q/A · filed 2023-02-06 | ||
| 2022-06-30 | 16.89K shares 10-Q · filed 2022-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |